9
Participants
Start Date
September 25, 2023
Primary Completion Date
January 14, 2025
Study Completion Date
March 10, 2025
BLU-263
BLU-263 Oral Tablets
Azacitidine
Azacitidine powder for suspension for intravenous infusion / subcutaneous injection
Antwerp University Hospital, Edegem
University Hospital Ghent, Ghent
CHU Caen - Institut d'Hematologie de Basse Normandie, Caen
Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Toledo
University of Michigan, Ann Arbor
University Medical Centre Mannheim, Mannheim
Huntsman Cancer Institute, Salt Lake City
Stanford Cancer Institute, Palo Alto
Dana-Farber Cancer Institute, Boston
Maastricht University Medical Center, Maastricht
Oslo University Hospital, Oslo
Lead Sponsor
Blueprint Medicines Corporation
INDUSTRY